The frequency explanations of side effects in package inserts, which were developed and tested in the PAINT1 study, received the recommendation of the EMA and various patients' organisations in September 2007 (PDF, see page 4).
The BfArM has recommended these frequency explanations, as developed by PAINT-Consult, since April 2007 (PDF).